Literature DB >> 25294227

Symptom Prevalence, Symptom Severity, and Health-Related Quality of Life Among Young, Middle, and Older Adults With Pulmonary Arterial Hypertension.

Lea Ann Matura1, Annette McDonough2, Diane L Carroll3.   

Abstract

Pulmonary arterial hypertension (PAH) is a chronic, life threatening illness that affects primarily women. The purpose of this study was to describe the prevalence of PAH symptoms and to determine whether there are differences in symptom severity and HRQOL in PAH symptoms among young, middle, and older adults with PAH. A cross sectional design was utilized. For all the age groups, shortness of breath (SOB) on exertion and fatigue were the two most prevalent symptoms. SOB on exertion had the highest symptom severity scores followed by fatigue for all groups. Symptom severity was significantly different among the groups for palpitations, abdominal swelling and nausea. For components of HRQOL, physical functioning worsened with age. All groups had diminished general health, role physical and vitality levels. There are some differences in symptom prevalence, symptom severity and HRQOL among young, middle and older adults. Awareness of these differences is important for healthcare providers to know and assess overtime. Palliative care should be an integral part of caring for patients with PAH.
© The Author(s) 2014.

Entities:  

Keywords:  aging; hypertension; pulmonary; quality of life; severity; symptoms

Mesh:

Year:  2014        PMID: 25294227     DOI: 10.1177/1049909114554079

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  8 in total

1.  An expert panel Delphi consensus statement on the use of palliative care in the management of patients with pulmonary arterial hypertension.

Authors:  Melisa Wilson; Rebekah H Anguiano; Rana L A Awdish; James C Coons; Amy Kimber; Melissa Morrison; Sara Paulus; Ann Schmit; Frank Spexarth; Keith M Swetz; Nathan J Verlinden; Mary E Whittenhall; Margaret R Sketch; Meredith Broderick; Jacqueline Brewer
Journal:  Pulm Circ       Date:  2022-01-05       Impact factor: 2.886

2.  The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension.

Authors:  Rubina M Khair; Chisom Nwaneri; Rachel L Damico; Todd Kolb; Paul M Hassoun; Stephen C Mathai
Journal:  Ann Am Thorac Soc       Date:  2016-06

3.  The Polish adaptation of the CAMbridge Pulmonary Hypertension Outcome Review (CAMPHOR).

Authors:  Katarzyna Małaczynska-Rajpold; Anna Smukowska-Gorynia; Alice Heaney; Stephen P McKenna; Magdalena Janus; Aleksander Araszkiewicz; Stanislaw Jankiewicz; Sylwia Slawek-Szmyt; Iga Tomaszewska; Tatiana Mularek-Kubzdela
Journal:  Cardiol J       Date:  2018-10-19       Impact factor: 2.737

4.  Palliative care in pulmonary hypertension associated with congenital heart disease: systematic review and expert opinion.

Authors:  Andrew Constantine; Robin Condliffe; Paul Clift; Robert Tulloh; Konstantinos Dimopoulos
Journal:  ESC Heart Fail       Date:  2021-03-03

5.  Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors.

Authors:  Todd M Tartavoulle; Aryn C Karpinski; Andrew Aubin; Benzi M Kluger; Oliver Distler; Lesley Ann Saketkoo
Journal:  ERJ Open Res       Date:  2018-03-23

6.  The importance of patient perspectives in pulmonary hypertension.

Authors:  Michael D McGoon; Pisana Ferrari; Iain Armstrong; Migdalia Denis; Luke S Howard; Gabi Lowe; Sanjay Mehta; Noriko Murakami; Brad A Wong
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

7.  Symptom phenotypes in pulmonary arterial hypertension: The PAH "symptome".

Authors:  Lea Ann Matura; Jamison D Fargo; Kathleen Boyle; Jason S Fritz; Kerri A Smith; Jeremy A Mazurek; Diane Pinder; Christine L Archer-Chicko; Harold I Palevsky; Allan I Pack; Marilyn S Sommers; Steven M Kawut
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

8.  Health-related quality of life, treatment adherence and psychosocial support in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Authors:  Bodil Ivarsson; Roger Hesselstrand; Göran Rådegran; Barbro Kjellström
Journal:  Chron Respir Dis       Date:  2018-07-16       Impact factor: 2.444

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.